Latest Breaking News On - Yrosine 4502 jp3463000004 - Page 1 : comparemela.com

Announced Agreement With Nimbus Therapeutics in December to Acquire a Potential Best-in-Class TYK2 Inhibitor, and with HUTCHMED in January to In-license Highly Selective, Oral Tyrosine Kinase. | February 2, 2023

United statesHong kongInternational financial reporting standardsEuropean commissionArrowhead pharmaceuticals incExchange commissionChina national medical products administrationNimbus therapeuticsTakeda pharmaceutical company limitedConstant exchange rateCosta saroukosLaunch productsFree cash flowDerived therapiesEmerging marketsMajor depressive disorder